11/30/2021, 12:15 PM (Source: TeleTrader)
more TeleTrader news

Regeneron: Omicron may reduce drug's potency

Regeneron Pharmaceuticals Inc. unveiled in a statement on Monday that its monoclonal antibody COVID-19 drug may be somewhat less effective against coronavirus' Omicron variant.

The company underlined that the prediction is not based on extensive data, but on "in vitro analyses and structural modeling," adding that further trials are needed to "confirm and quantify this potential impact."

Regeneron unveiled it will test other monoclonal antibodies against the new strain, and announced that the trial of the first Omicron-specific drug has already started.

Baha Breaking News (BBN) / BU